Sagimet Biosciences appoints Walbert and Hoelscher to board, raises $104.7M, extends cash runway to 2025 for Phase 3 trials of denifanstat.
Sagimet Biosciences appoints Tim Walbert and Paul Hoelscher to its board of directors to strengthen its leadership and industry experience as it progresses towards Phase 3 trials for its lead drug candidate, denifanstat, in metabolic dysfunction-associated steatohepatitis. The company has extended its cash runway to 2025 after raising $104.7 million in January 2024.
March 25, 2024
4 Articles